Despite major advances in ER-positive or HER2-amplified breast cancers, which can be targeted by drugs such as tamoxifen and trastuzumab (Herceptin), there is no targeted therapy currently available for TNBC. The gene discussed is ESR1; the disease is breast carcinoma.